SCHEMBL2826346

SCHEMBL2826346

CC(C)(C)c1cc(-c2ccccc2)c2c(c1)C(O)(C(F)(F)F)C(=O)O2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 1/20 0.64
GABBR1 Q9UBS5 1/20 0.64
GPR84 Q9NQS5 1/20 0.39
PDK2 Q15119 10/20 0.37
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PLA2G1B P04054 1/20 0.33
NFKB1 P19838 1/20 0.33
CASP3 P42574 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
TACR1 P25103 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2826352 1.00 GABBR2 (0.64) GABBR2GABBR1GPR84PDK2NPC1
SCHEMBL2826349 1.00 GABBR2 (0.64) GABBR2GABBR1GPR84PDK2NPC1
SCHEMBL2834138 0.92 GABBR2 (0.56) GABBR2GABBR1GPR84PDK2NPC1
SCHEMBL2371842 0.79 GABBR2 (1.00) GABBR2GABBR1
SCHEMBL2371840 0.79 GABBR2 (1.00) GABBR2GABBR1
SCHEMBL2371847 0.79 GABBR2 (1.00) GABBR2GABBR1
SCHEMBL30618192 0.79 GABBR2 (1.00) GABBR2GABBR1
SCHEMBL4598293 0.73 GABBR2 (0.46) GABBR2GABBR1PDK2
SCHEMBL2828609 0.73 GABBR2 (0.81) GABBR2GABBR1NPC1ALDH1A1RAB9A
SCHEMBL2829154 0.68 GABBR2 (0.74) GABBR2GABBR1PDK2ALDH1A1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1915357-B1 2-HYDROXY-PROPIONIC ACID DERIVATIVES AND 3-HYDROXY-BENZOFURAN-2-ONE DERIVATIVES WITH AFFINITY FOR THE GABA-B-RECEPTOR HOFFMANN LA ROCHE (CH) 2010-09-08 EP claimed
US-7504428-B2 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives HOFFMAN-LA ROCHE INC. (US) 2009-03-17 US claimed
US-20080234356-A1 2-PHENYL-3,3,3-TRIFLUORO-2-HYDROXY-PROPIONIC ACID DERIVATIVES MALHERBE PARICHEHR 2008-09-25 US claimed
US-20070027204-A1 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-02-01 US claimed
EP-1915357-B1 2-HYDROXY-PROPIONIC ACID DERIVATIVES AND 3-HYDROXY-BENZOFURAN-2-ONE DERIVATIVES WITH AFFINITY FOR THE GABA-B-RECEPTOR HOFFMANN LA ROCHE (CH) 2010-09-08 EP disclosed
US-7504428-B2 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives HOFFMAN-LA ROCHE INC. (US) 2009-03-17 US disclosed
US-20080234356-A1 2-PHENYL-3,3,3-TRIFLUORO-2-HYDROXY-PROPIONIC ACID DERIVATIVES MALHERBE PARICHEHR 2008-09-25 US disclosed
US-7396853-B2 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2008-07-08 US disclosed
US-20070027204-A1 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027204-A1 2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives GABRA3, GABRA2, GABRA1 GABBR2 6/4885GABBR1 4/4885GPR84 244/4885
US-20080234356-A1 2-PHENYL-3,3,3-TRIFLUORO-2-HYDROXY-PROPIONIC ACID DERIVATIVES GABBR1, GABRA2, GABRA3 GABBR2 5/4885GABBR1 1/4885GPR84 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.